Skip to main content
      RT @AurelieRheumo: 💻 Telemedicine: would you rather have a telephone or a video clinics? Non inferiority RCT shows 80

      Aurelie Najm AurelieRheumo

      4 years ago
      💻 Telemedicine: would you rather have a telephone or a video clinics? Non inferiority RCT shows 80% satisfaction rates and phone-only non-inferior to video visits. I would have expected patients to prefer video visits 🧐 #ACR21 #Abst0112 @RheumNow https://t.co/klgMJ6EthH https://t.co/17ffTAZCfv
      RT @ericdeinmd: #ACR21 Abst#0269
      ⭐️TCZ: ⬆️cholesterol, LDL, TG. ⬇️ hsCRP compared to TNFi. No ⬆️ risk of

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst#0269 ⭐️TCZ: ⬆️cholesterol, LDL, TG. ⬇️ hsCRP compared to TNFi. No ⬆️ risk of Reynold risk score (RRS) Take-away: good data on TCZ effect on lipids, but I wouldn't use RRS to calculate CVD risk on med that ⬇️ CRP @Rheumnow https://t.co/zMltktfHkS https://t.co/bwKXiGIi8a
      RT @Yuz6Yusof: #Abstr0076 #ACR21 Can we predict #thrombosis in #lupus patients? Predictors of serology transition at 5yr

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      #Abstr0076 #ACR21 Can we predict #thrombosis in #lupus patients? Predictors of serology transition at 5yrs: ✅LAC+ to LAC-:Afro-American,HCQ and normal C3 ⛔️LAC+ to 🩸Clot:Obesity, low C3 and not on HCQ Data need in those with Triple Positivity @RheumNow https://t.co/byeL5NjVUS https://t.co/CchtZir2GN
      RT @Yuz6Yusof: #Abstr0002 #ACR21 What drives salt in saliva in #sjogren? A study suggested Bcell cytokines mediated the

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      #Abstr0002 #ACR21 What drives salt in saliva in #sjogren? A study suggested Bcell cytokines mediated the epithelial Na+ Channel disruption. A case for targeting Bcell to improve oral health @RheumNow https://t.co/Bx3kBpOIFX https://t.co/YYnC6UoMJY
      RT @MeralElRamahiMD: Abst#0268
      ➡️Do lipids change w/ some bDMARDs in RA? YES!
      ⭐︎ TCZ: ↑ TC, LDL, TG & ↓

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      Abst#0268 ➡️Do lipids change w/ some bDMARDs in RA? YES! ⭐︎ TCZ: ↑ TC, LDL, TG & ↓ in hsCRP relative to initiating TNFi. ➡️Does this lipid ↑ confer risk for CVD? Not necessarily as it may not be atherogenic per Reynolds Risk Score! #ACR21 @Rheumnow https://t.co/Gy62mg6GhZ https://t.co/5uC8Zy0Lbr
      RT @KDAO2011: Which of the following would you d/c in the 3rd trimester of pregnancy? #ACR21 #Pregnancy @rheumnow

      TheDaoIndex KDAO2011

      4 years ago
      Which of the following would you d/c in the 3rd trimester of pregnancy? #ACR21 #Pregnancy @rheumnow
      RT @KDAO2011: Experts (Drs. M Clowse, Sammaratino) limit mAb TNFi 1 month b/f delivery or extend dosing. But, they do do

      TheDaoIndex KDAO2011

      4 years ago
      Experts (Drs. M Clowse, Sammaratino) limit mAb TNFi 1 month b/f delivery or extend dosing. But, they do dose again for flares. Risk for infection is low based on the PIANO registry. Postpartum, they restart the meds w/in 1 week (vag delivery), 2 weeks C/S @rheumnow #pregnancy
      RT @drdavidliew: In ANCA-associated vasculitis, does reverse seroconverting (ANCA+➡️ANCA-) make a difference?

      relap

      David Liew drdavidliew

      4 years ago
      In ANCA-associated vasculitis, does reverse seroconverting (ANCA+➡️ANCA-) make a difference? relapse - no ESRD - no death - no Don't measure serial ANCAs for prognosis (no diff MPO/PR3, RTX/CYC) target trial emulation @BrighamWomens @MGHrheumatology #ACR21 ABST0419 @RheumNow https://t.co/rLkTY0ul8f
      RT @Yuz6Yusof: Either we need to review the Yearly PAP cervical screening in SLE women or work hard to improve patient a

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      Either we need to review the Yearly PAP cervical screening in SLE women or work hard to improve patient awareness. Suspect the latter as time between tests was over 4 years late 😱 and 2.7% developed cancer #ACR21 #Abstr0133 @RheumNow https://t.co/wm01MfoFjf https://t.co/blD8WafZsE
      RT @ericdeinmd: #ACR21 Abst #0269: VA study of AutoAbs and CVD risk
      ⭐️Anti-malondialdehyde acetaldehyde (anti-MAA) s

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst #0269: VA study of AutoAbs and CVD risk ⭐️Anti-malondialdehyde acetaldehyde (anti-MAA) shown to associate w/ CVD risk in non-RA pt Findings: RF, CCP, anti-IgG anti-MAA, anti-IgM anti-MAA (not IgA) associated with ⬆️ CVD death https://t.co/WRBh673u8T @Rheumnow #ACRbest
      RT @KDAO2011: Dr. M Clowse (on HCQ during pregnancy):
      👉All pregnant women get HCQ 400 mg/day regardless of how big t

      TheDaoIndex KDAO2011

      4 years ago
      Dr. M Clowse (on HCQ during pregnancy): 👉All pregnant women get HCQ 400 mg/day regardless of how big they are (she does not dose based on mg/kg/d) 👉with maternal metabolism/volume distrib, levels are low. #ACR21 @rheumnow #pregnancy @drbags71 https://t.co/dZtFLdKOvk
      Industry Press Releases - BMS, Abbvie, UCB, Janssen

      The pharmaceutical companies will feature the results of their pivo

      Dr. John Cush RheumNow

      4 years ago
      Industry Press Releases - BMS, Abbvie, UCB, Janssen The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at #ACR21. https://t.co/RZwtACFZq7 https://t.co/guBG6PDVfp
      Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections. Over the past decade, an armamentarium of biologic and targeted therapies has led to better control of disease activity in patients with rheumatoid arthritis. Whether these patients, especially those receiving newer biological and targeted therapies such as JAK inhibitors, are at an increased risk of severe COVID-19
      RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. Al

      Dr. John Cush RheumNow

      4 years ago
      RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow and its Faculty.
      ×